PHARMA LITERATI

Pfizer Inc. announced the launch of its Vaccines Division’s Centers of Excellence Network, a global programme of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults. Pfizer Vaccines has designated the University of Louisville as its first Center of Excellence with a second global center anticipated in the first half of 2020. “ The Centers of Excellence will complete comprehensive, disease surveillance and real-world vaccine effectiveness studies, which are distinctly different from clinical safety and efficacy research ,” said Luis Jodar, Pfizer Vaccines, chief medical and scientific affairs officer. “ With strategically located research centers around the world, we anticipate being able to better define and understand global disease burden in adults and vaccine effectiveness, which will help prov...

New Delhi: In a setback to major domestic pharma companies like Cipla, Torrent, Emcure, Alkem, the Delhi High Court has granted an injunction restraining them from selling a medicine used for prevention and treatment of thromboembolic diseases, the patent for which is held by Bristol-Myers Squibb (BMS). BMS filed its claims for patent infringement in Delhi HC, arguing that its anticoagulant product, Apixaban, is patented till September 2022. The drug was granted a patent in 2011. BMS, along with partner Pfizer, has been selling the drug used in the prevention and treatment of blood clots under the brand name Eliquis. The US firm stated that it came to know on December 6 that Cipla was planning to launch the generic version of Apixaban under the probable brand name Apigy. BMS carried out an extensive market survey in Delhi to ascertain whether Cipla’s product was launched in the market or not, and it was revealed that the product was not available in the domestic market. ...